[English]  [Pусский]  [中文]  
 
ctt-journal > Shakhpazyan N.3 et al. (Abstract)

Shakhpazyan N.3 et al. (Abstract)

Cellular Therapy and Transplantation (CTT), Vol. 3, No. 12
doi: 10.3205/ctt-2011-No12-abstract41

© The Authors. This abstract is provided under the following license: Creative Commons Attribution 3.0 Unported

Abstract accepted for "5th Raisa Gorbacheva Memorial Meeting Hematopoietic Stem Cell Transplantation in Children and Adults", Saint Petersburg, Russia, September 18–20, 2011

Preliminary Program

Contribute a comment

 

Human mesenchymal stem cells for clinical use in children

Nicolay K. Shakhpazyan1, Irina V. Kobzeva1, Tatiana A. Astrelina1,2, Mariya V. Yakovleva1, Elena V. Skorobogatova3, Alexey E. Gomzyakov1, Elena V. Boyakova1,2, Elizaveta V. Kleina1, Yanna A. Kruglova1

1Stem Cell Bank, Moscow, Russia; 2Research Centre of Pediatric Hematology, Oncology and Immunology, Moscow, Russia; 3Russian Children's Clinical Hospital, Moscow, Russia

Correspondence: Tatiana A. Astrelina, Stem Cell Bank, Moscow, Russia, 31, Bakinskaya street, Moscow, 115541, Russia, E-mail: t_astrelina@spam is badmail.ru

Abstract

Aim: To present data about the use of human bone marrow mesenchymal stem cells (MSCs) in clinical practice.

Methods: Derived MSCs were given in the native or frozen form. A total of 70 MSCs doses were used in 23 patients (13 boys and 10 girls); median age was 7.0 years (range 1–18).

Results: MSC co-transplantation was performed in patients with the following diseases: ALL 4 (17%), biphenotypic acute leukemia 1 (4%), Fanconi's anemia 4 (17%), aplastic anemia 3 (13%); adrenoleukodystrophy 1 (4%), Wiskott-Aldrich syndrome 1 (4%), SCID 1 (4%); lymphohistiocytosis 2 (9%), CML 1 (4%), MDS 4 (17.4%), and osteopetrosis 1 (4%). The indications for co-transplantation of MSCs were: transplantation of HSC (in order to improve HSC engraftment and prevent GVHD) 11 (48%), chronic GVHD 2 (9%), acute GVHD 9 (39%), and HSCs transplant hypofunction in 1 case (4%). In all cases allogeneic bone marrow MSCs were used including 5 (7.1%) cases from relative donors (parents, sibling). The MSCs dose were 2, 1, 0.8 and 5.6 million per kg in 62 (88.6%), 5 (7.1%), 1 (1.4%) and 2 (2.9%) cases respectively. Ten (43%), 5 (22%), 2 (9%), 2 (9%), 1 (4%) and 1 (4%) and 2 (9%) patients received 1, 2, 3, 4, 6, 8, and 11 MSCs transplantations respectively. Acute reactions during and after the MSCs infusion were not observed. Donor chimerism was studied in order to evaluate the MSCs' engraftment. In 2 patients a temporary MSCs donor chimerism was seen.

Conclusions:
Thus, our data indicates the possibility of the clinical use of allogeneic human bone marrow MSCs, harvested under strict quality and safety control, in pediatric practice.

Keywords: mesenchymal stem cells, bone marrow, clinical use, safety, quality